Leukemia - Table of Contents alert Volume 28 Issue 10

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 28, Issue 10 (October 2014) In this issue Review Concise Review Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Nature Communications soon to be fully open access   From 20th October Nature Communications, will become fully open access for all new submissions. If an author has a manuscript they wish to submit to the journal via the subscription route, they must submit before 20th October. After this date all new submissions, if accepted, will be published open access and an article processing charge (APC) will apply. For any questions on the switch, open access or advice on policies and funding, visit our website, read the press release or contact our dedicated support team at openaccess@nature.com. Review Top Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease—friends or foes? A Balan, G Lucchini, S Schmidt, A Schneider, L Tramsen, S Kuçi, R Meisel, P Bader and T Lehrnbecher Leukemia 2014 28: 1941-1948; advance online publication, April 3, 2014; 10.1038/leu.2014.127 Abstract | Full Text Concise Review Top Should persons with acute myeloid leukemia have a transplant in first remission? R P Gale, P H Wiernik and H M Lazarus Leukemia 2014 28: 1949-1952; advance online publication, April 14, 2014; 10.1038/leu.2014.129 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial M Lazenby, A F Gilkes, C Marrin, A Evans, R K Hills and A K Burnett Leukemia 2014 28: 1953-1959; advance online publication, February 27, 2014; 10.1038/leu.2014.90 Abstract | Full Text THERAPY Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity K P Callahan, M Minhajuddin, C Corbett, E D Lagadinou, R M Rossi, V Grose, M M Balys, L Pan, S Jacob, A Frontier, M R Grever, D M Lucas, A D Kinghorn, J L Liesveld, M W Becker and C T Jordan Leukemia 2014 28: 1960-1968; advance online publication, February 28, 2014; 10.1038/leu.2014.93 Abstract | Full Text ACUTE LEUKEMIAS Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia R B Walter, G S Laszlo, J M Lionberger, J A Pollard, K H Harrington, C J Gudgeon, M Othus, S Rafii, S Meshinchi, F R Appelbaum and I D Bernstein Leukemia 2014 28: 1969-1977; advance online publication, March 18, 2014; 10.1038/leu.2014.107 Abstract | Full Text Functional integration of acute myeloid leukemia into the vascular niche C R Cogle, D C Goldman, G J Madlambayan, R P Leon, A Al Masri, H A Clark, S A Asbaghi, J W Tyner, J Dunlap, G Fan, T Kovacsovics, Q Liu, A Meacham, K L Hamlin, R A Hromas, E W Scott and W H Fleming Leukemia 2014 28: 1978-1987; advance online publication, March 18, 2014; 10.1038/leu.2014.109 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann, S Saussele, C Dietz, P Erben, A Fabarius, U Proetel, S Schnittger, S W Krause, J Schubert, H Einsele, M Hänel, J Dengler, C Falge, L Kanz, A Neubauer, M Kneba, F Stegelmann, M Pfreundschuh, C F Waller, K Spiekermann, G M Baerlocher, M Pfirrmann, J Hasford, W-K Hofmann, A Hochhaus, M C Müller and for the SAKK and the German CML Study Group Leukemia 2014 28: 1988-1992; advance online publication, May 6, 2014; 10.1038/leu.2014.153 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein N Purroy, P Abrisqueta, J Carabia, C Carpio, E Calpe, C Palacio, J Castellví, M Crespo and F Bosch Leukemia 2014 28: 1993-2004; advance online publication, March 12, 2014; 10.1038/leu.2014.96 Abstract | Full Text Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia D Saulep-Easton, F B Vincent, M Le Page, A Wei, S B Ting, C M Croce, C Tam and F Mackay Leukemia 2014 28: 2005-2015; advance online publication, March 18, 2014; 10.1038/leu.2014.105 Abstract | Full Text IMMUNOLOGY Comparative analysis of FoxP3+ regulatory T cells in the target tissues and blood in chronic graft versus host disease M M Imanguli, E W Cowen, J Rose, S Dhamala, W Swaim, S Lafond, B Yagi, R E Gress, S Z Pavletic and F T Hakim Leukemia 2014 28: 2016-2027; advance online publication, February 28, 2014; 10.1038/leu.2014.92 Abstract | Full Text ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells M Braig, N Pällmann, M Preukschas, D Steinemann, W Hofmann, A Gompf, T Streichert, T Braunschweig, M Copland, K L Rudolph, C Bokemeyer, S Koschmieder, A Schuppert, S Balabanov and T H Brümmendorf Leukemia 2014 28: 2028-2039; advance online publication, March 7, 2014; 10.1038/leu.2014.95 Abstract | Full Text Structural basis of Ets1 activation by Runx1 T Shrivastava, K Mino, N D Babayeva, O I Baranovskaya, A Rizzino and T H Tahirov Leukemia 2014 28: 2040-2048; advance online publication, March 20, 2014; 10.1038/leu.2014.111 Abstract | Full Text LYMPHOMA Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma A Moros, V Rodríguez, I Saborit-Villarroya, A Montraveta, P Balsas, P Sandy, A Martínez, A Wiestner, E Normant, E Campo, P Pérez-Galán, D Colomer and G Roué Leukemia 2014 28: 2049-2059; advance online publication, March 18, 2014; 10.1038/leu.2014.106 Abstract | Full Text MYELOMA Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma W I Gonsalves, S V Rajkumar, V Gupta, W G Morice, M M Timm, P P Singh, A Dispenzieri, F K Buadi, M Q Lacy, P Kapoor, M A Gertz and S K Kumar Leukemia 2014 28: 2060-2065; advance online publication, March 12, 2014; 10.1038/leu.2014.98 Abstract | Full Text p53 haploinsufficiency and functional abnormalities in multiple myeloma P J Teoh, T H Chung, S Sebastian, S N Choo, J Yan, S B Ng, R Fonseca and W J Chng Leukemia 2014 28: 2066-2074; advance online publication, March 14, 2014; 10.1038/leu.2014.102 Abstract | Full Text Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma E Kastritis, F Zagouri, A Symeonidis, M Roussou, A Sioni, A Pouli, S Delimpasi, E Katodritou, E Michalis, M Michael, E Hatzimichael, A Vassou, P Repousis, A Christophoridou, Z Kartasis, E Stefanoudaki, C Megalakaki, S Giannouli, M-C Kyrtsonis, K Konstantopoulos, M Spyroupoulou-Vlachou, E Terpos and M A Dimopoulos for the Greek Myeloma Study Group Leukemia 2014 28: 2075-2079; advance online publication, March 18, 2014; 10.1038/leu.2014.110 Abstract | Full Text PKA/AMPK signaling in relation to adiponectin’s antiproliferative effect on multiple myeloma cells E A Medina, K Oberheu, S R Polusani, V Ortega, G V N Velagaleti and B O Oyajobi Leukemia 2014 28: 2080-2089; advance online publication, March 20, 2014; 10.1038/leu.2014.112 Abstract | Full Text Letters to the Editor Top ETV6–FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant L Falchi, M Mehrotra, K J Newberry, L M Lyle, G Lu, K P Patel, R Luthra, U Popat and S Verstovsek Leukemia 2014 28: 2090-2092; advance online publication, May 23, 2014; 10.1038/leu.2014.168 Full Text Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification T Barbui, J Thiele, H M Kvasnicka, A Carobbio, A M Vannucchi and A Tefferi Leukemia 2014 28: 2092-2094; advance online publication, June 3, 2014; 10.1038/leu.2014.175 Full Text Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 S Manni, D Toscani, E Mandato, A Brancalion, L Quotti Tubi, P Macaccaro, A Cabrelle, F Adami, R Zambello, C Gurrieri, G Semenzato, N Giuliani and F Piazza Leukemia 2014 28: 2094-2097; advance online publication, June 4, 2014; 10.1038/leu.2014.178 Full Text Enhanced generation of cord blood hematopoietic stem and progenitor cells by culture with StemRegenin1 and Delta1Ext-IgG A Dahlberg, C Brashem-Stein, C Delaney and I D Bernstein Leukemia 2014 28: 2097-2101; advance online publication, June 6, 2014; 10.1038/leu.2014.181 Full Text Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells OPEN Y T Hsieh, E J Gang, S N Shishido, H N Kim, J Pham, S Khazal, A Osborne, Z A Esguerra, E Kwok, J Jang, H Bonig, R J Biediger, P Vanderslice and Y M Kim Leukemia 2014 28: 2101-2104; advance online publication, June 6, 2014; 10.1038/leu.2014.182 Full Text MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma C Fernández-Rodríguez, B Bellosillo, M García-García, B Sánchez-González, E Gimeno, M C Vela, S Serrano, C Besses and A Salar Leukemia 2014 28: 2104-2106; advance online publication, June 6, 2014; 10.1038/leu.2014.184 Full Text Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling L Eder-Azanza, D Navarro, P Aranaz, F J Novo, N C P Cross and J L Vizmanos Leukemia 2014 28: 2106-2109; advance online publication, June 12, 2014; 10.1038/leu.2014.190 Full Text B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) OPEN D L Petersen, T Krejsgaard, J Berthelsen, S Fredholm, A Willerslev-Olsen, N A Sibbesen, C M Bonefeld, M H Andersen, C Francavilla, J V Olsen, T Hu, M Zhang, M A Wasik, C Geisler, A Woetmann and N Odum Leukemia 2014 28: 2109-2112; advance online publication, June 12, 2014; 10.1038/leu.2014.192 Full Text Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition G W Gordon, J Monge, M B Channon, Q Wu, J L Skulan, A D Anbar and R Fonseca Leukemia 2014 28: 2112-2115; advance online publication, June 12, 2014; 10.1038/leu.2014.193 Full Text Advertisement NEW: Discounts on lab equipment The products you need at discounted prices! VISIT MARKETPLACE TODAY   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.